MedTrace Logo

Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer

NCT01125995 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2013-05-30

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and toxicity of different timing of concurrent chemoradiation in the treatment of limited disease status Small-cell lung cancer.

Conditions

Interventions

RADIATION

early CCRT

1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1. 2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy).

RADIATION

late CCRT

1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1. 2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy).

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Keunchil Park · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2011-07-31
Completion
2013-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125995 on ClinicalTrials.gov